Due to the lack of any effective therapy, novel approaches acidic protein (GFAP), an astrocyte specific protein. Two are currently being explored for the treatment of primary 1716 variants, 1774 and 1775, were constructed which brain tumours. It has previously been demonstrated that contain the GFAP-promoter element linked to the E. coli ␤-variants of HSV-1 which are deleted in the RL1 gene and galactosidase gene, inserted into the HSV-1 UL43 and fail to produce the virulence factor ICP34.5 are potential US5 loci, respectively. In primary cultures, human primary candidates for tumour therapy. The RL1 variant 1716 replitumour cell lines and established tumour cell lines in vitro, cates selectively within tumour cells and has the potential 1774 and 1775 gave high levels of expression of ␤-to deliver a therapeutic or tumour killing gene directly to galactosidase specifically in astrocytes. In vivo following the site of tumour growth. As many intracerebral tumours intracerebral inoculation, both viruses demonstrated high are glial and predominantly astrocytic in origin, we have levels of ␤-galactosidase expression predominantly in evaluated the ability of 1716 to deliver a reporter gene astrocytes. These results indicate that the GFAP promoter specifically to astrocytes in vivo and in vitro using a 2.2 kb element could be used for efficient and selective transgene fragment which controls expression of the glial fibrillary delivery to human gliomas.
Introduction
Herpes simplex virus (HSV) is a large double-stranded DNA virus, the genome of which consists of two unique segments, long and short, each bounded by a set of inverted repeats. HSV-1 expresses at least 84 known polypeptides which are involved mainly in regulation of gene expression and DNA replication, or are structural proteins. 1 The large genome size of HSV-1 and the relative ease with which foreign proteins can be cloned and expressed in the viral genome without any adverse effect on the replication of the virus has made it an attractive option as a vehicle for gene and cancer therapy. 2, 3 Large regions of the viral genome are non-essential for growth in tissue culture and could potentially be deleted to increase the cloning capacity of the virus further. Other advantages of HSV are its ability to infect cells which are either dividing or non-dividing, and its persistence within the host in a latent non-integrated form. This is particularly important for diseases which may require delivery of a therapeutic gene over a period of time.
For several years, we have been interested in the role of one particular gene, RL1 which is located in the repeat sequences flanking the long unique region of the virus genome. The product of this gene, ICP34.5, plays an important role in the virus life-cycle but its function is both cell type and cell state dependent. 4 In 3T6 cells, ICP34.5 is required for virus maturation and egress from the cell, 5 whereas in certain human cell lines, eg SK-N-SH, it has been shown that the function of ICP34.5 is to preclude host cell protein synthesis turn-off 6 through phosphorylation of eIF-2␣ by the activated protein kinase PKR. 7 Mutants which fail to synthesise ICP34.5 are non-neurovirulent following intracerebral inoculation of mice [8] [9] [10] [11] and typically have LD 50 values Ͼ10 6 p.f.u. higher than their parental wild-type virus. This non-neurovirulent phenotype is due to an inability to replicate in neurons of the central nervous system (CNS) following intracerebral inoculation. 10, 11 RL1 mutants replicate poorly at the periphery following footpad or corneal inoculation [12] [13] [14] yet they are still capable of establishing a latent infection. 12, 13 In vitro, RL1 mutants replicate as well as the parental virus in cells which are actively dividing, yet fail to replicate in cells which are serum-starved or growtharrested. 4, 10 The finding that RL1 mutant viruses replicate selectively in tumours of xenograph animal models but not in the surrounding terminally differentiated tissue of the CNS, [15] [16] [17] suggests they could provide a novel therapy for the treatment of human gliomas.
Tumour killing by RL1 mutant viruses could potentially be achieved in two ways: either by lysis of the tumour cell due to replication and release of progeny virus or by premature shut-off of cellular protein synthesis, leading to cell death. Furthermore, enhanced tumour killing could be achieved by modification of the virus to express a tumour-killing transgene or enzyme which can activate a prodrug. To achieve maximal levels of transgene expression, it may be necessary to utilize promoter elements which are tissue-or cell-type specific.
With the aim of identifying promoters which give targeted, high-level expression in the CNS, we have analysed the specificity and expression kinetics of a previously characterized promoter element 18 from the glial fibrillary acidic protein (GFAP), a highly conserved intermediate filament which is a specific marker for terminally differentiated astrocytes in the CNS. This promoter element confers astrocyte-specific expression to a ␤-galactosidase reporter gene in transgenic mice 19 and is particularly relevant to our studies since a large percentage of human CNS tumours are high-grade gliomas. Promoters which give high levels of transgene expression in astrocytes and other glial cells should be useful for delivery of a tumour killing gene. We have examined the effect of using the GFAP promoter on the efficacy and specificity of ␤-galactosidase reporter gene delivery, using 1716, 10 a RL1 null mutant of HSV-1.
Results
␤-Galactosidase expression in rat primary cell lines pGFa2lacZ contains a 2.2 kb fragment flanking the 5′ region of the human GFAP gene from np −2163 to +47 relative to the transcriptional start site of the mRNA. This fragment has previously been shown to direct gene expression specifically in astrocytes. 18 The region downstream of the RNA start site is critical for efficient transcription, and the initiating ATG at +15 bp has been changed to TTG by site-directed mutagenesis 19 so that protein synthesis initiates within the ␤-galactosidase gene. Mouse protamine 1 (mP1) structural gene sequences at the 3′ end of the ␤-galactosidase gene provide polyA addition sequences.
To determine the activity and specificity of GFAP promoter expression in vitro when flanked by HSV-1 sequences, primary cultures of rat astrocytes, dorsal root ganglia (DRG), Schwann, hippocampal and septal cells were transfected with 10 g p35-GFAP, fixed 48 h after transfection and stained to assay for ␤-galactosidase activity. p35CMV-lacZ was used as a positive control for transfection.
As has previously been shown, 20 GFAP promoter expression was detectable in primary astrocytes with no detectable expression in any other primary cell line tested demonstrating that the flanking HSV sequences did not affect specificity. The CMV immediate-early promoter was active in all cell lines. Other established cell lines of non-neuronal origin including BHK/C13 and 3T6 were tested for GFAP promoter expression following transfection of p35-GFAP but in all cases there was no ␤-galactosidase expression. In contrast, the plasmid containing the CMV immediate-early promoter demonstrated ␤-galactosidase expression in all cell lines tested.
Isolation of recombinant viruses
To determine the importance of position within the viral genome on specificity of expression from a foreign promoter, we analysed the effect of promoter insertion at two different locations (UL43 and US5) in the viral genome. A foreign promoter and reporter gene could potentially be inserted antisense to the US5 gene to give activity solely from the inserted promoter as the nearest upstream promoter is that of the US10 gene which is located more than 7 kb downstream of the 3′ end of US5. The UL43 locus on the other hand is in a region which contains abundant transcripts in both orientations including UL43 and UL43.5, 21 which maps antisense to UL43. Specificity of foreign promoter expression could potentially be affected by read-through from neighbouring promoters.
Two plasmids, p35-GFAP and pAT5.1-GFAP, were constructed, each containing a 5.8 kb BamHI fragment from the plasmid pGFa2lacZ. 18 Restriction enzyme digestion was used to determine the orientation of the fragment within the plasmid. In p35-GFAP the insert was in the sense orientation with respect to the UL43 transcript (Figure 1a) , whereas in pAT5.1 the insert was antisense to the US5 transcript (Figure 1b) . Both plasmids were linearized and cotransfected separately with intact 1716 DNA on to BHK cells. The GFAP promoter was not active in BHK cells therefore recombinant virus could not be detected using X-gal. The profiles of single plaque isolates from each transfection were analysed by Southern blotting and restriction endonuclease digestion to identify recombinant viruses. Two plaques were identified which contained the 5.8 kb insert in either UL43 or US5; these were purified and designated 1774 and 1775, respectively.
In 1774, the 5.8 kb insert is within the 6.6 kb BamHI i fragment and introduces two additional BamHI sites into this fragment. Therefore, digestion of 1774 with BamHI cleaves the BamHI i fragment into three novel fragments: one of 5.5 kb containing 3.3 kb of HSV-1 sequence (np 91610-np 94911) linked to 2.2 kb of GFAP promoter sequence; one of approximately 3 kb which consists entirely of ␤-galactosidase coding sequence; and a third fragment of 3.8 kb which contains the mP1 coding sequences and 3.3 kb of HSV-1 sequence from the lefthand end of BamHI i (np 94911-np98250). All three bands share homology with and are detectable using the 5.8 kb insert from pGFa2lacZ as a probe for Southern blotting (Figure 1c; lane 3) .
In 1775, the 5.8 kb insert is in the 6.4 kb BamHI j fragment and similarly, two additional BamHI sites are introduced into this fragment. Therefore digestion of 1775 with BamHI cleaves the BamHI j fragment into three novel fragments (Figure 1c ; lane 4): one of 7 kb containing 4.8 kb of HSV1 sequences from BamHI j (np 137945-142746) linked to 2.2 kb of GFAP promoter sequence, a band of approximately 3 kb identical to that found in 1774 which consists entirely of ␤-galactosidase coding sequence, and a third band of 2.1 kb which contains the mP1 coding sequences and 1.6 kb of HSV sequence from the right-hand end of BamHI j (np 136289-np 137945).
Characterization of GFAP promoter expression in nonastrocytic cells
In order to determine cell specificity of the GFAP promoter in the context of the viral genome, we assayed promoter activity in various cell lines. The fact that we had been unsuccessful in selecting recombinant viruses by screening transfection progeny plated on BHK/C13 under methyl-cellulose containing X-gal, indicated that the GFAP promoter was either inactive or expressed at 
Figure 1 Location of the 5.2 kb GFAP promoter/␤-galactosidase inserts in 1774 and 1775. This Figure shows a diagrammatic representation of the HSV-1 genome, with unique sequences represented by solid horizontal lines and repeat sequences represented by open squares. (a) In 1774, the 5.2 kb insert is located within the UL43 gene, and is orientated in the same direction as the UL43 transcript. (b) In 1775, the 5.2 kb insert is located within the US5 gene in an antisense orientation in relation to the US5 transcript. (c) DNA from 1716 (lane 2), 1774 (lane 3) and 1775 (lane 4) infected BHK/C13 cells was digested with

GFAP promoter expression in cells derived from the human CNS
The U-373MG glioma cell line was originally isolated from a patient with an anaplastic astrocytoma and contains Ͼ80% GFAP-positive cells. To determine whether 1774 and 1775 specifically expressed ␤-galactosidase in cells which endogenously expressed GFAP, U-373MG cells were separately infected with 1716, 1774, 1775 or 1716SV40 and double labelled to examine ␤-galactosidase and GFAP expression in individual cells. In 1716SV40-infected cultures, ␤-galactosidase activity was detectable regardless of the GFAP status of the infected cells. However in 1775 infected cultures, cells which were positive for GFAP (Figure 3a ) demonstrated ␤-galactosidase activity (Figure 3b ) whereas cells which were GFAPnegative failed to express detectable levels of the reporter gene. Identical results were also obtained in 1774-infected cultures.
1774 and 1775-infected cells were also double labelled using galactocerebroside, a specific marker of oligodendrocytes, as well as the ␤-galactosidase antibody. Approximately 10% of cells in the culture were positive for galactocerebroside and these failed to demonstrate detectable levels of ␤-galactosidase activity (data not shown).
Primary cultures of astrocytes were also infected with 1774 ( Figure 4 ) and 1775. As had been observed in the U-373MG cells similar levels of ␤-galactosidase activity were detectable with both viruses.
To assess the suitability of the GFAP promoter for delivery of a therapeutic transgene to primary human CNS tumours, we examined expression of the GFAP promoter in two low passage cells lines (BG555, analplastic astrocytoma and BG448, glioblastoma multiforme), obtained from human biopsy material. 22 These low ) gave high levels in both cell types. To determine whether changes in endogenous GFAP levels affected the level of GFAP promoter activity, both cell lines were passaged a further five times in vitro until endogenous GFAP expression was no longer detectable and infected with virus as above. There were high levels of ␤-galactosidase expression in cells infected with 1716SV40, however expression was only faintly detectable in cells infected with 1774 or 1775.
␤-Galactosidase expression from the GFAP promoter in vivo
To determine if the GFAP promoter gave selective expression in the CNS, 3-week-old BALB/c mice were separately inoculated in the left cerebral hemisphere with 10 5 p.f.u. of 1716, 1716SV40, 1774 or 1775. At various time-points up to 1 month after inoculation, brains were removed, fixed and cut into 8 sections. The site of viral inoculation was localised by staining for ␤-galactosidase. Sequential sections were reacted with polyclonal antibodies which recognise HSV-1 antigens, ␤-galactosidase and GFAP. In all cases, viral antigen was detectable until 5 days after inoculation and was predominantly localised to the region surrounding the needle tract ( Figure 6 ; bright purple staining). ␤-Galactosidase expression was detectable at 24 h after inoculation with all infecting viruses (Figure 7) . In 1716SV40-inoculated animals, expression was maximal at 3 days after inoculation and declined thereafter until by 14 days after inoculation ␤-galactosidase expression was barely detectable. The pattern of ␤-galactosidase expression was similar in 1774-and 1775-infected brains with maximal expression detected at 3 days after inoculation. At day 5 after inoculation, low levels of ␤-galactosidase expression were still evident around the needle tract but by day 14 only one or two cells stained positive.
A combination of immunohistochemical analysis and X-gal staining for the detection of ␤-galactosidase was used to co-localise GFAP and ␤-galactosidase expression. In 1716SV40-infected animals (Figure 7a ), ␤-galactosidase expression was detectable in cells which were both GFAP-positive and -negative and was confined to cells along the needle tract. In 1774- (Figure 7b ) and 1775- (Figure 7c ) infected animals ␤-galactosidase expression was also limited to the location of the needle tract and was detectable predominantly in cells which were also GFAP-positive. Sections were also double-labelled with antibodies which recognise the S-100 protein, another marker of astrocytes, neurofilament, a specific marker of neurons and galactocerebroside, a specific marker of oligodendrocytes. In 1716SV40-inoculated animals, ␤-galactosidase expression was detectable in cells which were positive for S-100 (Figure 8a To confirm that the GFAP promoter was inactive in cells of the PNS, pairs of 4-week-old female BALB/c mice were separately inoculated in the right rear footpad with 1716, 1774, 1775 and 1716pr9, a derivative of 1716 containing the LAT P1 promoter linked to the ␤-galactosidase gene and inserted into the HSV-1 UL43 locus. Six weeks after inoculation the dorsal root ganglia (DRG) were removed, fixed and stained for ␤-galactosidase activity. The DRG latently infected with 1716, 1774 or 1775 showed no detectable ␤-galactosidase staining neurons whereas those from mice infected with 1716pR9 stained positively as described previously. 23 
Discussion
The selective ability of HSV-1 RL1 mutants to replicate in tumour cells of nude mice bearing intracranial gliomas 15, 16, 24 without spread to adjacent tissue, has led to increasing interest in their use as a tool for the treatment
Figure 2 Localisation of the HSV-1 65 kDa DNA-binding protein and ␤-galactosidase in infected BHK/C13 cells. These photographs are representative examples of (a) 1716SV40-infected cells incubated with Z1F11; (b) 1716SV40-infected cells incubated with anti-␤-galactosidase; (c) 1775-infected cells incubated with Z1F11; (d) 1775-infected cells incubated with anti-␤-galactosidase. Magnification ×600.
of human gliomas. RL1 null mutants fail to replicate in the CNS of mice following intracerebral inoculation and are hence non-neurovirulent. [9] [10] [11] A recent study 25 has demonstrated that a double mutant containing a RL1 mutation and an additional deletion removing the large subunit of HSV ribonucleotide reductase is nonneurovirulent following intracerebral inoculation of owl monkeys, and it is predicted that RL1 null mutants and their derivatives should also fail to replicate in the human CNS.
Mutants which fail to synthesise ICP34.5 grow poorly in vitro in cells of neuronal origin and are specifically unable to prevent shut-off of host cell protein synthesis, 6 whereas infection of actively dividing cells predominantly results in sustained protein synthesis and production of infectious progeny. Therefore, RL1 mutant viruses could provide a double hit phenomenon whereby cell death would occur not only through lysis owing to growth and release of replicating virus, but also by shutoff of host cell protein synthesis. Moreover, additional tumour cell killing could be achieved by delivery of a tumour killing transgene, prodrug activator or inhibitor of cellular proliferation. Tumour killing would not necessarily require prolonged transgene expression, but highlevel expression targeted to specific subsets of cells would undoubtedly be advantageous.
Although RL1 mutants fail to replicate in the CNS following intracerebral inoculation, studies using in situ hybridization to detect the HSV-1 latency-associated transcripts (LATS) have demonstrated that the RL1 mutant 1716 can establish a latent infection selectively in neurons of the CNS. 24, 26 Hence, if 1716 is to be utilised as a vector for delivery of genes to human CNS tumours whose products are cytotoxic, it will be necessary to utilise promoters which are inactive in neurons, to prevent destruction of the neuron should a latent infection occur. As astrocytes comprise one of the major cell populations of the vertebrate CNS, and high-grade gliomas are the most common human CNS tumours, we decided that a promoter which gave strong specific expression in glial cells but which was inactive in neurons could be a suitable candidate.
As a starting point for these studies we chose to examine a well characterised promoter element which drives expression of the astrocyte-specific marker, GFAP. Expression of GFAP, the principal cytoskeletal protein in astrocytes, is a hallmark of astrocytic differentiation during development. 27 Following CNS injury, either as a result of trauma, disease or genetic disorder, astrocytes become reactive and respond in a manner termed astrogliosis. In an experimental counterpart to intracerebral injury, it has already been demonstrated 18 that a needle stab wound to the brains of mice, leads to an upregulation of GFAP activity as demonstrated by the increase in levels of expression of a ␤-galactosidase reporter gene in a transgenic mouse model. Therefore direct inoculation of a virus which contains a transgene controlled by the GFAP promoter, into a tumour mass should lead to an overproduction of the transgene in the surrounding area.
In this study, we utilized a 2.2 kb fragment of DNA which is located 5′ to the human GFAP gene and has been shown to drive astrocyte specific expression in cultured cells, 20 and transgenic mice. 18 As promoter specificity could be lost in the context of the virus genome, due to the influence of nearby promoter elements, two different sites, the UL43 and US5 loci were chosen for insertion. The in vivo and in vitro data yielded similar results for both viruses, indicating that the 2.2 kb 5′-flanking fragment confers specificity irrespective of the insertion site.
In a range of established cell lines from different species and human tumour cell lines in vitro, endogenous GFAP expression was required for reporter gene expression from the GFAP promoter. This suggests that in vitro, similar factors regulate expression from both the exogenous and endogenous promoters. Immunohistochemical experiments which were carried out to examine expression in vivo demonstrated that ␤-galactosidase expression was mainly confined to GFAP-positive cells, although some cells which demonstrated ␤-galactosidase expression did not appear to express GFAP. Whether this is due to insensitivity of the antibody used or non-astrocytic expression is presently unclear but the findings that (1) ␤-galactosidase expression was not detectable in cells which expressed neurofilament or galactocerebrosidase, specific markers of neurons and oligodendrocytes, respectively; and (2) cells which expressed ␤-galactosidase but did not label with GFAP, labelled with an antibody which recognises the S-100 protein, which is also a marker of astrocytes, would suggest that the former is the case. Therefore it would appear that in vivo as well as in vitro, the GFAP promoter does confer astrocytespecific expression to the ␤-galactosidase reporter gene.
The finding that ␤-galactosidase expression is not detectable in cells which are expressing neurofilament demonstrates that the GFAP promoter is inactive in neurons of the CNS, and if the GFAP promoter is to be used for delivery of a cytotoxic transgene, it is a prerequisite that the promoter should be inactive during latency. We have demonstrated that DRG explanted from mice latently infected with 1774 or 1775 do not demonstrate detectable levels of ␤-galactosidase, indicating that the GFAP promoter is inactive in PNS neurons during the latent state. Low level expression of ␤-galactosidase in DRG neurons was detectable from the LAT promoter up to 3 months (the latest time-point examined in this study) following footpad inoculation, as has previously been demonstrated. 23 It would be predicted therefore that the GFAP promoter would also be inactive in neurons of the CNS during a latent HSV infection. This is supported by the failure to detect ␤-galactosidase expression in cells of the CNS at time-points later than 2 weeks after inoculation.
If 1716 is utilised as a gene delivery agent for astrocytic tumours where expression of a cytotoxic protein would be used additionally to the selective replication competence of 1716 per se, then the enhanced specificity of high-level expression in glial cells provided by the GFAP promoter should provide sufficient targeting to CNS tumours. Future experiments in rodent models will be used to examine the efficacy of this promoter for transgene delivery to CNS tumour-bearing animals.
Materials and methods
Cells
Baby hamster kidney clone 13 cells (BHK-21/C13) 28 were propagated in Eagle's medium containing twice the normal concentration of vitamins and amino acids, 5% tryptose phosphate broth and 10% (v/v) newborn calf serum. U-373MG (obtained from the European Tissue Culture Collection (Salisbury, UK)) and the human primary glioma cell lines BG448 and BG555 22 were propagated in a 50:50 mixture of Ham's F-10 medium and Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal calf serum, 5% l-glutamine and 50 g ml −1 gentamicin. Dissociated cultures of rat primary astrocytes, DRG, septal, hippocampal and Schwann cells were prepared from newborn Sprague-Dawley rats essentially as previously described 29 for foetal cultures.
Viruses
Virus stocks were grown and titrated on BHK21/C13 cells, as previously described. The parental wild-type HSV-1 strain used in this study was Glasgow strain 17 + , 30 and the parental RL1 mutant was 1716. 10 1716pR9 23 and 1716SV40 31 (AR MacLean, personal communication) were used as positive controls for some experiments. These viruses contain the LAT P1 and SV40 promoters, respectively, linked to a ␤-galactosidase reporter gene and inserted in the HSV-1 UL43 locus.
Generation of recombinant viruses
The plasmid p35 contains a BamHI-EcoRI fragment of HSV-1 DNA (np 91610-967511) cloned into the vector pGEM-2. 31 This plasmid has been modified by insertion of a double stranded oligonucleotide containing a multicloning site with a unique BglII site at the unique NsiI site (np 94911) within UL43 and was provided by Dr A McGregor (Division of Virology, Glasgow University, UK). A 5.2 kb BamHI fragment from the plasmid pGFa2l-acZ, 18 containing a 2.2 kb fragment from the GFAP promoter linked to a ␤-galactosidase reporter gene was cloned into the unique BglII site in p35 to produce the plasmid p35-GFAP.
The plasmid pAT/5.1 (obtained from R Reid, MRC Virology Unit, Glasgow, UK) which contains the HSV-1 sequences np 136289-139328 cloned into pAT153 has similarly been modified to contain a multicloning site containing a unique BglII site by insertion of a double stranded oligonucleotide into the unique SacI (np 137945) site in the US5 locus. The 5.2 kb BamHI fragment from pGFa2lacZ1 was similarly cloned into the unique BglII site in pAT/5.1 to produce the plasmid pAT/5.1-GFAP.
Both plasmids were linearised and separately transfected on to BHK/C13 cells with 1716 DNA. Plates were incubated at 37°C until cytopathic effect (c.p.e.) was com- plete, harvested and titrated to give individual plaques. DNA from individual plaques was prepared and analysed by Southern blotting. 32 Once recombinant viruses had been identified they were plaque purified three times before growing up a virus stock.
Transient transfection
Sixty per cent confluent monolayers of cells were transfected with 10 g plasmid DNA using Transfectam Reagent (Promega, Southampton, UK) in accordance with the manufacturer's recommended instructions. Cells were fixed using 4% paraformaldehyde at room temperature for 10 min 48 h after transfection, washed twice with PBS and stained to assay for ␤-galactosidase expression using a solution containing 5 mm potassium ferrocyanide, 5 mm potassium ferricyanide, 2 mm magnesium chloride, and 1 mg/ml X-gal in PBS (X-gal medium).
p35-CMVlacZ which contains the CMV immediateearly promoter linked to the ␤-galactosidase gene in the UL43 locus of p35 was used as a positive control for transfection.
Immunofluorescence
Linbro wells containing coverslips were seeded with approximately 5 x 10 4 cells and incubated at 37°C overnight. Cells on coverslips were mock-infected or infected with virus at a MOI of 1 p.f.u. per cell. Following incubation at 37°C for 16 h, cells were fixed with 4% paraformaldehyde for 15 min at room temperature, washed twice with phosphate-buffered saline (PBS) and stored in 70% ethanol at −20°C until use.
Coverslips were incubated for 2 h at room temperature initially with either a monoclonal antibody Z1F11, which recognises the HSV-1 65K DNA-binding protein (kindly provided by Dr H Marsden, MRC Virology Unit, Glasgow) at a 1:1000 dilution, a monoclonal antibody (Europath, Cornwall, UK) against GFAP at a 1:200 dilution, or a monoclonal antibody (Boehringer Mannheim, East Sussex, UK) against galactocerebrosidase at a 1:200 dilution. When staining for galactocerebroside, antibody incubations were carried out before fixation of the cells. Fluoresceine isothiocyanate-conjugated goat anti-mouse IgG (Europath) was used as a second antibody. Coverslips were then incubated with a polyclonal antibody which recognises ␤-galactosidase (Harlan Sera-Labs, Sussex, UK). In this case rhodamine-conjugated goat anti-rabbit IgG was used as a second antibody (Europath). Incubations of second antibody were carried out for 1 h at room temperature. Cells were mounted in Citifluor (UKC Chemical, Canterbury, UK) and viewed using a Nikon Microphot SA microscope (Surrey, UK).
Animal studies
To analyse promoter expression in the CNS in vivo, 3-week-old female BALB/c mice were inoculated into the left cerebral hemisphere with 25 l of an appropriate virus dilution in PBS containing 10% newborn calf serum (PBS/calf). At various times after inoculation, animals were killed, their brains removed and fixed in 4% paraformaldehyde for 3-4 h on ice. Brains were equilibrated in 10%, 20% and 30% sucrose (in PBS containing 10 mm MgCl 2 ) and frozen in OCT compound (Raymond Lamb, London, UK) before sectioning. For analysis of promoter expression in the peripheral nervous system, 4-week-old female BALB/c mice were inoculated in the right rear footpad with 25 l virus dilution in PBS/calf. DRG from latently infected animals were explanted 6 weeks after viral inoculation and stained for the presence of ␤-galactosidase. The DRG were removed, fixed in 4% paraformaldehyde for 1 h at 4°C, washed twice with PBS and incubated at 37°C in a mixture containing 5 mm potassium ferricyanide, 5 mm potassium ferrocyanide, 2 mm MgCl 2 , 0.02% NP40, 0.02% sodium deoxycholate and 1 mg/ml X-gal in PBS.
Immunohistochemistry
Brains from animals inoculated into the left cerebral hemisphere were cut into 8 sections on a Bright Cryostat with rotary microtome (Bright Instrument, Huntingdon, UK). Every 10th section was stained for the presence of ␤-galactosidase, as described above. Once the boundaries of the needle wound had been identified, the sections in between were used either for analysis of viral antigen expression with a polyclonal HSV-1 antibody (Dako, High Wycombe, UK) at a 1:5000 dilution, or to examine ␤-galactosidase expression, using a polyclonal antibody (Harlan Sera-Labs) at a 1:1000 dilution. GFAP expression was detected using a monoclonal antibody (Europath) at a 1:1000 dilution.
GFAP and ␤-galactosidase colocalization studies on mouse CNS tissue were also carried out using immunofluoresence with antibody dilutions and incubation times, as described above. In addition, monoclonal antibodies against neurofilament (Affiniti, Nottingham, UK) and S-100 (Sigma, Poole, UK) were used at dilutions of 1:1000.
Sections were stained using a Vectastain ABC kit (Vector Laboratories, Peterborough, UK) in accordance with the manufacturer's recommended instructions, with 3,3′-diaminobenzidine (DAB) or Vector VIP as substrates for the enzyme peroxidase.
